Latest NewsNov 4, 2024HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200604, a Best-in-Class BTLA Agonist Antibody for the Treatment of Inflammatory and Immunology Diseases All Filter By: Year2024202320222021202020192018201720162015Life Science Success Podcast | Podcast | Jan 5, 2023HiFiBiO Therapeutics CEO Liang Schweizer Interviewed by Life Science Success PodcastNov 18, 2022HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200603 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid TumorsSep 5, 2022HiFiBiO Therapeutics to Present Trial in Progress Poster for HFB301001 at 2022 ESMO CongressAug 15, 2022HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200301 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid TumorsApr 27, 2022HiFiBiO Therapeutics to Present Trial in Progress Poster for HFB200301 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting< 1 … 3 4 5 6 7 … 17 >
